{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:31:51Z","timestamp":1761129111619},"reference-count":34,"publisher":"Informa UK Limited","issue":"sup1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Chemotherapy"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1179\/joc.2005.17.supplement-1.5","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T19:21:19Z","timestamp":1389295279000},"page":"5-11","source":"Crossref","is-referenced-by-count":7,"title":["Tigecycline \u2013 The First Glycylcycline to Undergo Clinical Development: An Overview of<i>In Vitro<\/i>Activity Compared to Tetracycline"],"prefix":"10.1080","volume":"17","author":[{"given":"D.","family":"Felmingham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.1.1"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.5.4.387"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161280401221007113202","volume":"4","author":"Sum PE","year":"1998","journal-title":"Curr Pharm Des"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2270"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(01)00081-9"},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","volume":"43","author":"Petersen PJ","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinmicnews.2004.10.001"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1096"},{"key":"CIT0010","first-page":"38","volume":"1994","author":"Wexler HM","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.534"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1864"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00034-6.x"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00198-9"},{"key":"CIT0015","first-page":"44","volume":"2000","author":"Hoellman DB","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0016","first-page":"2745","volume":"44","author":"Goldstein EJ","year":"2000","journal-title":"Antimicrob. Agents Chemother"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00092-9"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00269-3"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00355-7"},{"key":"CIT0020","unstructured":"Heine HS, Dicks R, Andrews G. In vitro activity of ori-tavancin (LY 333328), levofloxacin, meropenem, GAR-936 and linezolid against strains of Bacillus anthracis. 41\u201d Intersciece Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, US, 2001."},{"key":"CIT0021","first-page":"2604","volume":"45","author":"Kenny GE","year":"2001","journal-title":"pneumoniae and Ureaplasma ure-alyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin and telithromycin compared to their susceptibilities to refer-ence macrolides, tetracyclines and quinolones. Antimicrob Agents Chemother"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.892-895.2002"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.3.479"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf196"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2595-2601.2002"},{"key":"CIT0026","first-page":"46","volume":"2002","author":"Wallace RJ","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00332-7"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.533-540.2003"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.400-404.2003"},{"key":"CIT0030","first-page":"63","volume":"64","author":"Zhanel GG","year":"2004","journal-title":"A comparative review with the tetracyclines. Drugs"},{"key":"CIT0031","first-page":"36","volume":"2004","author":"Fritsche TR","journal-title":"Diagn Microbiol Infect Dis"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.08.007"},{"key":"CIT0033","first-page":"44","volume":"2000","author":"Boucher HN","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0034","unstructured":"CLSI. Performance standards for antimicrobial suscepti-bility testing; Fifteenth Informational Supplement. CLSI Document M100-515 (ISBN 1-56238-55619), CLSI, Wayne, Pennsylvania 19087-1898, US, 2005."}],"container-title":["Journal of Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10256018808623883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T18:10:47Z","timestamp":1688926247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1179\/joc.2005.17.Supplement-1.5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":34,"journal-issue":{"issue":"sup1","published-online":{"date-parts":[[2013,12,13]]},"published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1179\/joc.2005.17.Supplement-1.5"],"URL":"https:\/\/doi.org\/10.1179\/joc.2005.17.supplement-1.5","relation":{},"ISSN":["1120-009X","1973-9478"],"issn-type":[{"value":"1120-009X","type":"print"},{"value":"1973-9478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}